about us

press release






FDA Updates

Clinical Trials

Medical Device News

Past News

LabCentral Announces $22.4 M In Committed Funding for LabCentral 238 Including New Sponsors Thermo Fischer Scientific and Waters Corporation

LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, today announced a total of $22.4 million in sponsorship commitments for LabCentral 238, a fully functional life sciences laboratory with a focus on scale-up bio-manufacturing. Thermo Fisher Scientific...

Evox Therapeutics Completes £69.2 Million Series C Financing

Financing round significantly oversubscribed by both new and existing investors. Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform

Micronoma Raises $3.5 Million in Convertible Note Financing

February 17, 2021 Micronoma the first cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, notes contributions came from existing investor, US-based SymBiosis, LLC, and new European...

Theravectys Secures $20M in Funding

With the current unmet need for vaccines that safely and effectively treat these diseases, there comes a need for a new approach to how these vaccines are created. Theravectys’ lentiviral vectors are engineered to elicit an unprecedented, efficient cellular immune response through direct in vivo transduction of dendritic cells.

Cambrian Biopharma Announces $60M in Financing

February 9, 2021 Cambrian Biopharma, a Distributed Drug Discovery Company (DisCo), announced that it has raised $60 million in private financing to develop medicines to extend healthy lifespan. Cambrian Biopharma is a multi-asset biotechnology company that combines the advantages of a...

Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing

The merger and financing, which include conversion of outstanding debt, was led by Allele Capital Partners LLC. Howard Berman, Ph.D., has been appointed as Chief Executive Officer and a member of the Company’s Board of Directors.

Avacta Group Announces AffyXell Secures $7.3 Million In Series A Financing

Avacta Group notes the funds will be used to further develop its pipeline of next generation cell and gene therapies.

ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies

ARCH Venture Partners will invest Fund XI in early-stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, and ways of reimagining diagnostics and therapies.

Innodem Neurosciences Receives $6 Mil US Dollars of Financing From Morningside Group

The company reports their mobile software technology is embodied in an application that turns a tablet or a smartphone into a device capable of capturing Eye Movement Biomarkers and Gaze Mapping Biomarkers accurately within minutes in order to assist a clinician's diagnosis.

Latest News

Accuredit Therapeutics and N1 Life Form a Joint Venture Named ‘Napoltec’, Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical...

"We are very pleased to establish a new joint venture, Napoltec, with N1 Life, which will be featuring complementary in mutually pursuing gene therapy drug development. The N1 Life team led by Dr. Zang and Prof. Wender has accumulated years of research and development experience in novel delivery systems.

FDA Releases Federal Interagency Working Group Scientific Opinions on Testing Methods for Asbestos in Talc-Containing Cosmetic Products

Release of the white paper concludes the efforts of the IWGACP. The FDA will consider the scientific opinions presented in the white paper, including having it peer-reviewed, as part of its overall efforts to help ensure the safety of talc-containing cosmetic products.

Hekka Labs Introduces the First Decentralized Chronic Disease Data Management Ecosystem in South Asia

Hekka has cemented initial partnerships with 3 Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which as recently agreed to provide a minimum of 1.5 million medical records in 2022.

Impact NRS LLC Creates RumenEra Inc to Develop and Commercialize High-Impact Rumen Microbiome Applications in a Joint Collaboration with National Institute for Biotechnology in...

Mr. Salman continues "RumenEra is committed to the creation of a global reference standard for the rapid measurement of net feed efficiency, as well as creating products that can be applied to ruminants to optimize their efficiency while decreasing environmental burdens, naturally and healthily, for both the animals and their ecosystems."

Join Medical Device News Magazine's Mailing List: Receive a Weekly Recap of Device Industry News